AU2022273023A1 - Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine - Google Patents

Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine Download PDF

Info

Publication number
AU2022273023A1
AU2022273023A1 AU2022273023A AU2022273023A AU2022273023A1 AU 2022273023 A1 AU2022273023 A1 AU 2022273023A1 AU 2022273023 A AU2022273023 A AU 2022273023A AU 2022273023 A AU2022273023 A AU 2022273023A AU 2022273023 A1 AU2022273023 A1 AU 2022273023A1
Authority
AU
Australia
Prior art keywords
count
nadir
baseline
absolute neutrophil
human subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022273023A
Other languages
English (en)
Inventor
William B. AINSWORTH
John Hayslip
Steve H. KYE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of AU2022273023A1 publication Critical patent/AU2022273023A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2022273023A 2021-05-11 2022-05-10 Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine Abandoned AU2022273023A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163201749P 2021-05-11 2021-05-11
US63/201,749 2021-05-11
PCT/US2022/028429 WO2022240786A1 (en) 2021-05-11 2022-05-10 Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine

Publications (1)

Publication Number Publication Date
AU2022273023A1 true AU2022273023A1 (en) 2023-11-23

Family

ID=84028499

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022273023A Abandoned AU2022273023A1 (en) 2021-05-11 2022-05-10 Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine

Country Status (11)

Country Link
US (1) US20220378811A1 (enExample)
EP (1) EP4337183A4 (enExample)
JP (1) JP2024517318A (enExample)
KR (1) KR20240006659A (enExample)
CN (1) CN117642161A (enExample)
AU (1) AU2022273023A1 (enExample)
BR (1) BR112023023677A2 (enExample)
CA (1) CA3219760A1 (enExample)
IL (1) IL308321A (enExample)
MX (1) MX2023013364A (enExample)
WO (1) WO2022240786A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3258941A4 (en) * 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
JP7585231B2 (ja) * 2019-04-29 2024-11-18 イミュノジェン， インコーポレイテッド 抗ｃｄ１２３免疫複合体を含む治療的組み合わせ
WO2020257671A1 (en) * 2019-06-20 2020-12-24 Celgene Corporation Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
WO2021037933A1 (en) * 2019-08-28 2021-03-04 Astrazeneca Ab Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer
PH12022550835A1 (en) * 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia

Also Published As

Publication number Publication date
IL308321A (en) 2024-01-01
CN117642161A (zh) 2024-03-01
CA3219760A1 (en) 2022-11-17
JP2024517318A (ja) 2024-04-19
US20220378811A1 (en) 2022-12-01
BR112023023677A2 (pt) 2024-02-20
KR20240006659A (ko) 2024-01-15
EP4337183A1 (en) 2024-03-20
WO2022240786A1 (en) 2022-11-17
MX2023013364A (es) 2023-11-27
EP4337183A4 (en) 2025-04-23

Similar Documents

Publication Publication Date Title
JP6726252B2 (ja) 骨髄抑制の処置
EP3890740B1 (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
McKeage et al. Basiliximab: a review of its use as induction therapy in renal transplantation
WO2006119395A2 (en) Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection
US20220370481A1 (en) Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with a cyp3a inhibitor and azacitidine
EP4337183A1 (en) Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine
TW202200202A (zh) 非耗竭性抗ｃｄ６單株抗體於治療細胞激素風暴之用途
Kromer et al. Response of recalcitrant generalized morphea to intravenous immunoglobulins (IVIg): three cases and a review of the literature
Bonaros et al. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation
Goland et al. Induction therapy with thymoglobulin after heart transplantation: impact of therapy duration on lymphocyte depletion and recovery, rejection, and cytomegalovirus infection rates
Rodríguez Management of the adverse effects of lenalidomide in multiple myeloma
Lutfi et al. The emergence of bispecific T-cell engagers in the treatment of follicular and large B-cell lymphomas
El Cheikh et al. Risk-adapted approach to HLA-matched sibling hematopoietic cell allografting: impact of adjusting conditioning intensity and integrating post-transplant therapeutic interventions
HK40106739A (en) Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine
Heslop et al. Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1
HK40106881A (en) Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with a cyp3a inhibitor and azacitidine
WO2025223394A1 (en) Combination therapy for classic hodgkin's lymphoma
WO2025122961A1 (en) Methods for treating neutropenia
WO2025209478A1 (en) Methods of treatment warm autoimmune hemolytic anemia using sovleplenib
CN121358495A (zh) 用于治疗系统性硬化症的免疫球蛋白制剂
JP2025537848A (ja) 多発性硬化症の治療方法
WO2026091825A1 (zh) 抗cd3/cd20双特异性抗体在制备用于治疗cd20阳性b-nhl的药物中的用途
TW202423968A (zh) Ｃｄ３８結合融合蛋白組合療法
Schmitt et al. CLINICAL NEPHROLOGY-EPIDEMIOLOGY-CLINICAL TRIALS Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): An open study in 15 patients.
Graham et al. 01 Cytokine Release Syndrome

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period